Cybersecurity Top Reason The FDA Rejects Medical Device Submissio
Cybersecurity Top Reason The FDA Rejects Medical Device Submissio
Publish Date: 2026-05-10 15:13:00
Source Domain: natlawreview.com
FDA premarket rejections have surged since the February 2026 cybersecurity guidance. Espinosa speaks at MedTech World North America, May 11–13.
Cybersecurity has quietly become the single most overlooked reason a medical device launch falls apart. The companies winning in 2026 treat it as a design input, not a finish-line checklist.”
— Christian Espinosa, Founding CEO
WEST PALM BEACH, FL, UNITED STATES, May 10, 2026 /EINPresswire.com/ — When the FDA finalized its updated cybersecurity guidance for medical devices in February 2026, it set a higher bar that much of the industry is still scrambling to meet. Premarket submissions are being rejected at a higher rate, timelines are slipping, and capital is sitting on the sidelines waiting for clarity.
That is the message Christian Espinosa, Founding CEO of Blue Goat Cyber, will bring to MedTech World North America 2026, the inaugural U.S. edition of the global MedTech summit series, taking place May 11–13 at the Hilton West Palm Beach.
“Cybersecurity has quietly become the single most overlooked reason a medical device launch falls apart,” said Espinosa, a white hat hacker, Air Force veteran, and bestselling author of The Smartest Person in the Room. “Founders raise capital, run trials, and build commercial teams, then get blindsided in cyber review. The companies winning in 2026 are the ones treating cybersecurity as a design input, not a documentation exercise at the finish line.”
A Critical Inflection Point for MedTech
Blue Goat Cyber, a Title Sponsor of the summit, has supported FDA premarket submissions across surgical robots, breakthrough designation devices, in vitro diagnostics, AI-enabled software as a medical device, implantables, diagnostic imaging systems, and wearable health monitors. The firm has watched the regulatory bar rise sharply since the FDA’s September 2023 draft guidance, with the February 2026 final version raising it further still.
The firm’s expanded presence at MedTech World…
